Oxford BioMedica plc OXB
LSE · United Kingdom · Health Technology
GBp 516.00-6.00 (-1.15%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...
Oxford BioMedica PLC (OXBDF) posted GBP80.2 million in H1 2026 revenue, signed 17 new clients, and reaffirmed full-year guidance of GBP180-200 million despite a GBP7.6 million France site impairment.
Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Gene Transfer Technologies Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.The global Gene Transfer Technologies Market is projected to witness robust growth during the forecast period from 2026 to 2036, driven by the rapid expansion of gene and cell therapies, increasing investments in genomic medicine, and continuous advancements in vector engine
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.